Leerink Swann Equities Analysts Boost Earnings Estimates for Thermo Fisher Scientific Inc (TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) – Stock analysts at Leerink Swann lifted their FY2017 earnings estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Thursday. Leerink Swann analyst P. Souda now anticipates that the medical research company will earn $9.34 per share for the year, up from their prior estimate of $9.26. Leerink Swann currently has a “Outperform” rating and a $207.00 target price on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q3 2018 earnings at $2.62 EPS, Q3 2019 earnings at $2.98 EPS and FY2019 earnings at $11.70 EPS.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.03 earnings per share. TRADEMARK VIOLATION WARNING: “Leerink Swann Equities Analysts Boost Earnings Estimates for Thermo Fisher Scientific Inc (TMO)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/10/30/leerink-swann-equities-analysts-boost-earnings-estimates-for-thermo-fisher-scientific-inc-tmo.html.

Several other equities analysts have also recently commented on TMO. Citigroup Inc. restated a “buy” rating and issued a $201.00 target price (up from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. BidaskClub upgraded shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research report on Tuesday, July 11th. Wells Fargo & Company restated an “outperform” rating and issued a $200.00 target price (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, Barclays PLC restated an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $205.50.

Shares of Thermo Fisher Scientific (NYSE TMO) opened at 192.42 on Monday. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $201.20. The firm’s 50-day moving average is $191.73 and its 200 day moving average is $178.12. The company has a market capitalization of $75.07 billion, a PE ratio of 33.52 and a beta of 1.05.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the transaction, the senior vice president now owns 67,016 shares in the company, valued at approximately $11,796,156.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,738 shares of company stock worth $9,302,112. Insiders own 0.49% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank lifted its position in shares of Thermo Fisher Scientific by 57.0% during the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after acquiring an additional 16,308 shares during the period. BB&T Securities LLC raised its holdings in Thermo Fisher Scientific by 4.4% during the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in Thermo Fisher Scientific by 2.1% during the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock worth $8,327,000 after buying an additional 977 shares during the last quarter. Mitchell Capital Management Co. raised its holdings in Thermo Fisher Scientific by 40.3% during the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after buying an additional 12,910 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in Thermo Fisher Scientific by 0.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares during the last quarter. Institutional investors own 83.47% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit